Elvin Wagenblast, PhD
img_Elvin Wagenblast
ASSISTANT PROFESSOR | Oncological Sciences
ASSISTANT PROFESSOR | Pediatrics, Hematology/Oncology
Research Topics
Blood, Cancer Genetics, Leukemia, Stem Cells
Multi-Disciplinary Training Area
Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS], Genetics and Genomic Sciences [GGS]
Leveraging Genome Editing to Study Childhood Leukemia
The central question of his lab is to understand how a normal blood stem cell can become cancerous. In leukemia, the initiating genetic mutations occur as early as during fetal development. His team applies cutting-edge CRISPR/Cas9 genome editing approaches in human primary blood stem cells to model the pre-leukemic and leukemic phases of acute myeloid and acute lymphoblastic leukemia in vivo. The goal is to uncover insights into the genetic, cellular and developmental mechanisms of leukemia, with a particular focus on childhood leukemia, and identify therapeutic vulnerabilities of the disease.

BSc, Heidelberg University, Germany

PhD, Cold Spring Harbor Laboratory, NY

Postdoctoral, Princess Margaret Cancer Center, Canada

American Society of Hematology Scholar Award

Leukemia and Lymphoma Society Special Fellow

Alex’s Lemonade Stand Foundation Young Investigator

Human Frontier Science Program Fellowship

Banting Fellowship

Boehringer Ingelheim Fonds Fellowship

Fulbright Fellowship

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Wagenblast did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.